[1] LanX, Li Z M, Zhang M Z. Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately[J]. Cancer Res Clin Oncol, 2018, 144(7):1265-1277.
[2] 郁文亮,李智惠,于丽丽.利妥昔单抗单药治疗HIV阳性的多中心型Castleman病患者疗效的Meta分析[J]. 药物生物技术, 2018,25(2): 135-141.
[3] Abid M B, Stromich J, Gundacker N D, et al. Is ibrutinib associated with disseminated cryptococcosis with CNS involvement[J]. Cancer Biol Ther, 2018, 27: 1-3.
[4] Patel M, IKeda S, Pilat S R, et al. JAK1 Genomic Alteration associated with exceptional response to siltuximab in cutaneous castleman disease[J]. JAMA Dermatol, 2017, 153(5): 449-452.
[5] Yoshizaki Y, Shinichi M, Hirok I, et al.The role of interleukin-6 in castleman disease[J]. Hematol Oncol Clin North Am, 2018, 32(1): 23-36.
[6] Zhu S H, Yu Y H, Zhang Y, et al. Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients[J]. Med Oncol, 2013, 30(1): 492. |
